Update on the pathophysiological implications and clinical role of angiogenic factors in pregnancy

Fetal Diagnosis and Therapy

Volumn 37, Issue 2, 2015, Pages 81-92

  Llurba, Elisa ^a,b   Crispi, Fatima ^c   Verlohren, Stefan ^d  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Angiogenesis; Congenital heart defects; Intrauterine growth restriction; Preeclampsia; Uteroplacental insufficiency

Indexed keywords

ANGIOGENIC FACTOR; ENDOGLIN; PLACENTAL GROWTH FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; BIOLOGICAL MARKER; PLACENTA PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADVERSE OUTCOME; ANGIOGENESIS; CARDIOVASCULAR RISK; CONGENITAL HEART MALFORMATION; ENDOTHELIAL DYSFUNCTION; HEART DEVELOPMENT; HUMAN; INTRAUTERINE GROWTH RETARDATION; PATHOPHYSIOLOGY; PERIPARTUM CARDIOMYOPATHY; PLACENTA INSUFFICIENCY; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; REVIEW; STILLBIRTH; THIRD TRIMESTER PREGNANCY; ANIMAL; BLOOD; FEMALE; NEOVASCULARIZATION, PATHOLOGIC; PREGNANCY COMPLICATIONS;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; BIOMARKERS; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84924341744     PISSN: 10153837     EISSN: 14219964     Source Type: Journal    
DOI: 10.1159/000368605     Document Type: Review

References (97)

1. Romero R, Kusanovic JP, Chaiworapongsa T, Hassan SS: Placental bed disorders in preterm labor, preterm PROM, spontaneous abortion and abruptio placentae. Best Pract Res Clin Obstet Gynaecol 2011; 25: 313-327.
2. Charnock-Jones DS, Kaufmann P, Mayhew TM: Aspects of human fetoplacental vasculogenesis and angiogenesis. I. Molecular regulation. Placenta 2004; 25: 103-113.
3. Kaufmann P, Mayhew TM, Charnock-Jones DS: Aspects of human fetoplacental vasculogenesis and angiogenesis. II. Changes during normal pregnancy. Placenta 2004; 25: 114-126.
4. Wilting J, Birkenhager R, Eichmann A, Kurz H, Martiny-Baron G, Marme D, McCarthy JE, Christ B, Weich HA: VEGF121 induces proliferation of vascular endothelial cells and expression of flk-1 without affecting lymphatic vessels of chorioallantoic membrane. Dev Biol 1996; 179: 76-85.
5. Andraweera PH, Dekker GA, Roberts CT: The vascular endothelial growth factor family in adverse pregnancy outcomes. Hum Reprod Update 2012; 18: 436-457.
6. De Wolf F, De Wolf-Peeters C, Brosens I, Robertson WB: The human placental bed: electron microscopic study of trophoblastic invasion of spiral arteries. Am J Obstet Gynecol 1980; 137: 58-70.
7. Meekins JW, Pijnenborg R, Hanssens M, Mc-Fadyen IR, van Asshe A: A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol 1994; 101: 669-674.
8. Shore VH, Wang TH, Wang CL, Torry RJ, Caudle MR, Torry DS: Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast. Placenta 1997; 18: 657-665.
9. Ziche M, Maglione D, Ribatti D: Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Lab Invest 1997; 76: 517-531.
10. Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH: Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn 2011; 31: 66-74.
11. Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, Alitalo K, Damsky C, Fisher SJ: Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002; 160: 1405-1423.
12. Woods AK, Hoffmann DS, Weydert CJ, Butler SD, Zhou Y, Sharma RV, Davisson RL: Adenoviral delivery of VEGF121 early in pregnancy prevents spontaneous development of preeclampsia in BPH/5 mice. Hypertension 2011; 57: 94-102.
13. Burton GJ, Woods AW, Jauniaux E, Kingdom JC: Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta 2009; 30: 473-482.
14. Cudmore M, Ahmad S, Al-Ani B, Fujisawa T, Coxall H, Chudasama K, Devey LR, Wigmore SJ, Abbas A, Hewett PW, Ahmed A: Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 2007; 115: 1789-1797.
15. Zhao H, Wong RJ, Kalish FS, Nayak NR, Stevenson DK: Effect of heme oxygenase-1 deficiency on placental development. Placenta 2009; 30: 861-868.
16. Roberts J: Pre-eclampsia a two-stage disorder: what is the linkage? Are there directed fetal/placental signals? In Lyall F, Belfort M (eds): Pre-Eclampsia: Etiology and Clinical Practice. New York, Cambridge University Press, 2007, pp 183-194.
17. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658.
18. Karumanchi SA, Epstein FH: Placental ischemia and soluble fms-like tyrosine kinase 1: cause or consequence of preeclampsia? Kidney Int 2007; 71: 959-961.
19. Kendall RL, Thomas KA: Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 1993; 90: 10705-10709.
20. Lu F, Longo M, Tamayo E, Maner W, Al-Hendy A, Anderson GD, Hankins GD, Saade GR: The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am J Obstet Gynecol 2007; 196: 396.e1-e7.
21. Gilbert JS, Babcock SA, Granger JP: Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 2007; 50: 1142-1147.
22. Bergmann A, Ahmad S, Cudmore M, Gruber AD, Wittschen P, Lindenmaier W, Christofori G, Gross V, Gonzalves ACh, Grone HJ, Ahmed A, Weich HA: Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J Cell Mol Med 2010; 14: 1857-1867.
23. Romundstad PR, Magnussen EB, Smith GD, Vatten LJ: Hypertension in pregnancy and later cardiovascular risk: common antecedents? Circulation 2010; 122: 579-584.
24. Tei C, et al: New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function-A study in normals and dilated cardiomyopathy. J Cardiol 1995; 26: 357-366.
25. Kasner M, et al: Utility of Doppler echocardiography and tissue Doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction: a comparative Doppler-conductance catheterization study. Circulation 2007; 116: 637-647.
26. Patten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L, Hacker MR, Rhee JS, Mitchell J, Mahmood F, Hess P, Farrell C, Koulisis N, Khankin EV, Burke SD, Tudorache I, Bauersachs J, del Monte F, Hilfiker-Kleiner D, Karumanchi SA, Arany Z: Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 2012; 485: 333-338.
27. Melchiorre K, Sutherland GR, Liberati M, Thilaganathan B: Preeclampsia is associated with persistent postpartum cardiovascular impairment. Hypertension 2011; 58: 709-715.
28. Kirk R: Bevacizumab and heart failure. Nat Rev Clin Oncol 2011; 8: 124.
29. Uraizee I, Cheng S, Moslehi J: Reversible cardiomyopathy associated with sunitinib and sorafenib. N Engl J Med 2011; 365: 1649-1650.
30. Hochholzer W, Reichlin T, Stelzig C, Hochholzer K, Meissner J, Breidthardt T, Reiter M, Duehsler B, Freidank H, Winkler K, Twerenbold R, Mueller C: Impact of soluble fms-like tyrosine kinase-1 and placental growth factor serum levels for risk stratification and early diagnosis in patients with suspected acute myocardial infarction. Eur Heart J 2011; 32: 326-335.
31. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, VandenDriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persico MG: Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001; 7: 575-583.
32. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA; CPEP Study Group: Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992-1005.
33. Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ: Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 2010; 122: 478-487.
34. Romero R, Nien JK, Espinoza J, et al: A longitudinal study of angiogenic (placental growth factor) and anti-Angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008; 21: 9-23.
35. De Vivo A, Baviera G, Giordano D, Todarello G, Corrado F, DAnna R: Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand 2008; 87: 837-842.
36. Moore Simas TA, Crawford SL, Solitro MJ, Frost SC, Meyer BA, Maynard SE: Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 2007; 197: 244.e1-e8.
37. Crispi F, Llurba E, Dominguez C, Martin-Gallan P, Cabero L, Gratacos E: Predictive value of angiogenic factors and uterine artery Doppler for early-versus late-onset pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 2008; 31: 303-309.
38. Stepan H, Geipel A, Schwarz F, Kramer T, Wessel N, Faber R: Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol 2008; 198: 175.e1-e6.
39. Espinoza J, Romero R, Nien JK, et al: Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 2007; 196: 326.e1-e13.
40. Crispi F, Dominguez C, Llurba E, Martin-Gallan P, Cabero L, Gratacos E: Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol 2006; 195: 201-207.
41. Chaiworapongsa T, Romero R, Kim YM, et al: Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005; 17: 3-18.
42. Erez O, Romero R, Espinoza J, et al: The change in concentrations of angiogenic and anti-Angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008; 21: 279-287.
43. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest JC, Giguere Y: Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-Analysis. Obstet Gynecol 2010; 116: 402-414.
44. Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH: First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009; 53: 812-818.
45. Wright D, Akolekar R, Syngelaki A, Poon LC, Nicolaides KH: A competing risks model in early screening for preeclampsia. Fetal Diagn Ther 2012; 32: 171-178.
46. Poon LC, Akolekar R, Lachmann R, Beta J, Nicolaides KH: Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks. Ultrasound Obstet Gynecol 2010; 35: 662-670.
47. Crovetto F, Figueras F, Triunfo S, Crispi F, Rodriguez-Sureda V, Peguero A, Dominguez C, Gratacos E: Added value of angiogenic factors for the prediction of early and late preeclampsia in the first trimester of pregnancy. Fetal Diagn Ther 2014; 35: 258-266.
48. Berg CJ, Callaghan WM, Syverson C, Henderson Z: Pregnancy-related mortality in the United States, 1998 to 2005. Obstet Gynecol 2010; 116: 1302-1309.
49. Zhang J, Meikle S, Trumble A: Severe maternal morbidity associated with hypertensive disorders in pregnancy in the United States. Hypertens Pregnancy 2003; 22: 203-212.
50. Crispi F, Dominguez C, Llurba E, Martin-Gallan P, Cabero L, Gratacos E: Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol 2006; 195: 201-207.
51. Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH: Combined screening for preeclampsia and small for gestational age at 11-13 weeks. Fetal Diagn Ther 2013; 33: 16-27.
52. Scazzocchio E, Figueras F, Crispi F, Meler E, Masoller N, Mula R, Gratacos E: Performance of a first-trimester screening of preeclampsia in a routine care low-risk setting. Am J Obstet Gynecol 2013; 208: 203.e1-e10.
53. Crovetto F, Crispi F, Scazzocchio E, Mercade I, Meler E, Figueras F, Gratacos E: First-trimester screening for early and late small-forgestational-Age neonates using maternal serum biochemistry, blood pressure and uterine artery Doppler. Ultrasound Obstet Gynecol 2014; 43: 34-40.
54. Chaiworapongsa T, Romero R, Korzeniewski SJ, Kusanovic JP, Soto E, Lam J, Dong Z, Than NG, Yeo L, Hernandez-Andrade E, Conde-Agudelo A, Hassan SS: Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. Am J Obstet Gynecol 2013; 208: 287.e1-e15.
55. Lai J, Pinas A, Poon LC, Agathokleous M, Nicolaides KH: Maternal serum placental growth factor, pregnancy-Associated plasma protein-A and free β-human chorionic gonadotrophin at 30-33 weeks in the prediction of pre-eclampsia. Fetal Diagn Ther 2013; 33: 164-172.
56. Lai J, Syngelaki A, Poon LC, Nucci M, Nicolaides KH: Maternal serum soluble endoglin at 30-33 weeks in the prediction of preeclampsia. Fetal Diagn Ther 2013; 33: 149-155.
57. Figueras F, Gratacos E: Update on the diagnosis and classification of fetal growth restriction and proposal of a stage-based management protocol. Fetal Diagn Ther 2014; 36: 86-98.
58. Gomez-Arriaga PI, Herraiz I, Lopez-Jimenez EA, Gomez-Montes E, Denk B, Galindo A: Uterine artery Doppler and sFlt-1/PlGF ratio: usefulness in diagnosis of pre-eclampsia. Ultrasound Obstet Gynecol 2013; 41: 530-537.
59. Schlembach D, Wallner W, Sengenberger R, et al: Angiogenic growth factor levels in maternal and fetal blood: correlation with Doppler ultrasound parameters in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 2007; 29: 407-413.
60. Herraiz I, Droge LA, Gomez-Montes E, Henrich W, Galindo A, Verlohren S: Characterization of the soluble fms-like tyrosine kinase-1 to placental growth factor ratio in pregnancies complicated by fetal growth restriction. Obstet Gynecol 2014; 124: 265-273.
61. Stepan H, Kramer T, Faber R: Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab 2007; 92: 2831-2834.
62. Triunfo S, Lobmaier S, Parra-Saavedra M, Crovetto F, Peguero A, Nadal A, Gratacos E, Figueras F: Angiogenic factors at diagnosis of late-onset small-for-gestational age and histological placental underperfusion. Placenta 2014; 35: 398-403.
63. Benton SJ, Hu Y, Xie F, Kupfer K, Lee SW, Magee LA, von Dadelszen P: Can placental growth factor in maternal circulation identify fetuses with placental intrauterine growth restriction? Am J Obstet Gynecol 2012; 206: 163. e1-e7.
64. Lobmaier SM, Figueras F, Mercade I, Perello M, Peguero A, Crovetto F, Ortiz JU, Crispi F, Gratacos E: Angiogenic factors vs Doppler surveillance in the prediction of adverse outcome among late-pregnancy small-for-gestational-Age fetuses. Ultrasound Obstet Gynecol 2014; 43: 533-540.
65. Staff AC, Benton SJ, von Dadelszen P, et al: Redefining preeclampsia using placenta-derived biomarkers. Hypertension 2013; 61: 932-942.
66. Robertson WB, Brosens I, Dixon HG: The pathological response of the vessels of the placental bed to hypertensive pregnancy. J Pathol Bacteriol 1967; 93: 581-592.
67. Khong TY, De Wolf F, Robertson WB, Brosens I: Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986; 93: 1049-1059.
68. Zhou Y, Fisher SJ, Janatpour M, et al: Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion? J Clin Invest 1997; 99: 2139-2151.
69. Pijnenborg R, Anthony J, Davey D, et al: Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol 1991; 98: 648-655.
70. Zhang J, Klebanoff MA, Roberts JM: Prediction of adverse outcomes by common definitions of hypertension in pregnancy. Obstet Gynecol 2001; 97: 261-267.
71. Fisher KA, Luger A, Spargo BH, Lindheimer MD: Hypertension in pregnancy: clinicalpathological correlations and remote prognosis. Medicine (Baltimore) 1981; 60: 267-276.
72. Stepan H, Unversucht A, Wessel N, Faber R: Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007; 49: 818-824.
73. Stepan H, Unversucht A, Wessel N, Faber R: Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007; 49: 818-824.
74. Diab AE, El-Behery MM, Ebrahiem MA, Shehata AE: Angiogenic factors for the prediction of pre-eclampsia in women with abnormal midtrimester uterine artery Doppler velocimetry. Int J Gynaecol Obstet 2008; 102: 146-151.
75. Chaiworapongsa T, Espinoza J, Gotsch F, et al: The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonatal Med 2008; 21: 25-40.
76. Schoofs K, Grittner U, Engels T, et al: The importance of repeated measurements of the sFlt-1/PlGF ratio for the prediction of preeclampsia and intrauterine growth restriction. J Perinat Med-2014; 42: 61-68.
77. Verlohren S, Galindo A, Schlembach D, et al: An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010; 202: 161.e1-e11.
78. Ohkuchi A, Hirashima C, Suzuki H, et al: Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia. Hypertens Res 2010; 33: 422-427.
79. Schiettecatte J, Russcher H, Anckaert E, et al: Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia. Clin Biochem 2010; 43: 768-770.
80. Verlohren S, Herraiz I, Lapaire O, et al: New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension 2014; 63: 346-352.
81. Rana S, Powe CE, Salahuddin S, et al: Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012; 125: 911-919.
82. Rana S, Hacker MR, Modest AM, et al: Circulating angiogenic factors and risk of adverse maternal and perinatal outcomes in twin pregnancies with suspected preeclampsia. Hypertension 2012; 60: 451-458.
83. Rana S, Schnettler WT, Powe C, et al: Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy 2013; 32: 189-201.
84. Ness RB, Roberts JM: Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications. Am J Obstet Gynecol 1996; 175: 1365-1370.
85. Verlohren S, Herraiz I, Lapaire O, et al: The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012; 206: 58.e1-e8.
86. Verlohren S, Melchiorre K, Khalil A, Thilaganathan B: Uterine artery Doppler, birth weight and timing of onset of pre-eclampsia: providing insights into the dual etiology of late-onset pre-eclampsia. Ultrasound Obstet Gynecol 2014; 44: 293-298.
87. Klingel R, Gohlen B, Schwarting A, Himmelsbach F, Straube R: Differential indication of lipoprotein apheresis during pregnancy. Ther Apher Dial 2003; 7: 359-364.
88. Thadhani R, Kisner T, Hagmann H, et al: Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011; 124: 940-950.
89. Miquerol L, Langille BL, Nagy A: Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. Development 2000; 127: 3941-3946.
90. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, OShea KS, Powell-Braxton L, Hillan KJ, Moore MW: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380: 439-442.
91. Lee YM, Cope JJ, Ackermann GE, Goishi K, Armstrong EJ, Paw BH, Bischoff J: Vascular endothelial growth factor receptor signaling is required for cardiac valve formation in zebrafish. Dev Dyn 2006; 235: 29-37.
92. Armstrong EJ, Bischoff J: Heart valve development: endothelial cell signaling and differentiation. Circ Res 2004; 95: 459-470.
93. Llurba E, Sanchez O, Ferrer Q, Nicolaides KH, Ruiz A, Dominguez C, Sanchez-de-Toledo J, Garcia-Garcia B, Soro G, Arevalo S, Goya M, Suy A, Perez-Hoyos S, Alijotas-Reig J, Carreras E, Cabero L: Maternal and foetal angiogenic imbalance in congenital heart defects. Eur Heart J 2014; 35: 701-707.
94. Llurba E, Syngelaki A, Sanchez O, Carreras E, Cabero L, Nicolaides KH: Maternal serum placental growth factor at 11-13 weeks gestation and fetal cardiac defects. Ultrasound Obstet Gynecol 2013; 42: 169-174
95. Ikeda E, Achen MG, Breier G, Risau W: Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 1995; 270: 19761-19766.
96. Levy AP, Levy NS, Goldberg MA: Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem 1996; 271: 2746-2753.
97. Davis EF, Lazdam M, Lewandowski AJ, Worton SA, Kelly B, Kenworthy Y, Adwani S, Wilkinson AR, McCormick K, Sargent I, Redman C, Leeson P: Cardiovascular risk factors in children and young adults born to preeclamptic pregnancies: a systematic review. Pediatrics 2012; 129:e1552-e1561.